Kaposi sarcoma-associated herpesvirus and response to antiretroviral therapy: A prospective study of HIV-infected adults
Identifieur interne : 001913 ( Pmc/Corpus ); précédent : 001912; suivant : 001914Kaposi sarcoma-associated herpesvirus and response to antiretroviral therapy: A prospective study of HIV-infected adults
Auteurs : Mhairi Maskew ; A Patrick Macphail ; Denise Whitby ; Matthias Egger ; Matthew P. FoxSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1525-4135 ] ; 2013.
Abstract
The possible impact of co-infection with Kaposi’s sarcoma associated herpes virus on the response to antiretroviral therapy (ART) is unknown. Prospective studies are rare, particularly in Africa.
We enrolled a prospective cohort of HIV-infected adults initiating ART in Johannesburg, South Africa. Subjects were defined as seropositive to KSHV if reactive to either KSHV lytic K8.1 or latent Orf73 antigen or both. Subjects were followed from ART initiation until 18-months on treatment. HIV viral load and CD4 counts were tested 6 monthly. Linear generalized estimating and log-binomial regression models were used to estimate the effect of KSHV infection on immunologic recovery and response as well as HIV viral load suppression within 18-months after ART initiation.
385 subjects initiating ART from November 2008-March 2009 were eligible including 184 (48%) KSHV+. The KSHV+ group was similar to the KSHV− in terms of age, gender, initiating CD4 count, body mass index, tuberculosis and haemoglobin levels. The KSHV+ group gained a similar number of cells at 6- (difference of 10 cells/mm3, 95% CI: −11–31), 12- (3 cells/mm3, 95% CI: −19–25) and 18-months (24 cells/mm3, 95% CI: −13–61) compared to the KSHV− group. Adjusted relative risk of failure to suppress viral load to <400 copies/mL (1.03; 95% CI: 0.90–1.17) were similar for KSHV+ and KSHV− by 6-months on treatment.
In a population with a high KSHV prevalence, HIV-positive adults co-infected with KSHV achieved similar immunologic and virologic responses to ART early after treatment initiation compared to those KSHV−.
Url:
DOI: 10.1097/QAI.0b013e3182969cc1
PubMed: 23614996
PubMed Central: 3712196
Links to Exploration step
PMC:3712196Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Kaposi sarcoma-associated herpesvirus and response to antiretroviral therapy: A prospective study of HIV-infected adults</title><author><name sortKey="Maskew, Mhairi" sort="Maskew, Mhairi" uniqKey="Maskew M" first="Mhairi" last="Maskew">Mhairi Maskew</name><affiliation><nlm:aff id="A1">Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</nlm:aff></affiliation></author><author><name sortKey="Macphail, A Patrick" sort="Macphail, A Patrick" uniqKey="Macphail A" first="A Patrick" last="Macphail">A Patrick Macphail</name><affiliation><nlm:aff id="A2">Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</nlm:aff></affiliation></author><author><name sortKey="Whitby, Denise" sort="Whitby, Denise" uniqKey="Whitby D" first="Denise" last="Whitby">Denise Whitby</name><affiliation><nlm:aff id="A3">Viral Oncology Section, AIDS and Cancer Virus Program, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick MD, USA</nlm:aff></affiliation></author><author><name sortKey="Egger, Matthias" sort="Egger, Matthias" uniqKey="Egger M" first="Matthias" last="Egger">Matthias Egger</name><affiliation><nlm:aff id="A4">Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Fox, Matthew P" sort="Fox, Matthew P" uniqKey="Fox M" first="Matthew P." last="Fox">Matthew P. Fox</name><affiliation><nlm:aff id="A1">Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</nlm:aff></affiliation><affiliation><nlm:aff id="A5">Center for Global Health and Development, Boston, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A6">Department of Epidemiology, Boston University School of Public Health, Boston, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23614996</idno><idno type="pmc">3712196</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712196</idno><idno type="RBID">PMC:3712196</idno><idno type="doi">10.1097/QAI.0b013e3182969cc1</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">001913</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001913</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Kaposi sarcoma-associated herpesvirus and response to antiretroviral therapy: A prospective study of HIV-infected adults</title><author><name sortKey="Maskew, Mhairi" sort="Maskew, Mhairi" uniqKey="Maskew M" first="Mhairi" last="Maskew">Mhairi Maskew</name><affiliation><nlm:aff id="A1">Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</nlm:aff></affiliation></author><author><name sortKey="Macphail, A Patrick" sort="Macphail, A Patrick" uniqKey="Macphail A" first="A Patrick" last="Macphail">A Patrick Macphail</name><affiliation><nlm:aff id="A2">Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</nlm:aff></affiliation></author><author><name sortKey="Whitby, Denise" sort="Whitby, Denise" uniqKey="Whitby D" first="Denise" last="Whitby">Denise Whitby</name><affiliation><nlm:aff id="A3">Viral Oncology Section, AIDS and Cancer Virus Program, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick MD, USA</nlm:aff></affiliation></author><author><name sortKey="Egger, Matthias" sort="Egger, Matthias" uniqKey="Egger M" first="Matthias" last="Egger">Matthias Egger</name><affiliation><nlm:aff id="A4">Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Fox, Matthew P" sort="Fox, Matthew P" uniqKey="Fox M" first="Matthew P." last="Fox">Matthew P. Fox</name><affiliation><nlm:aff id="A1">Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</nlm:aff></affiliation><affiliation><nlm:aff id="A5">Center for Global Health and Development, Boston, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A6">Department of Epidemiology, Boston University School of Public Health, Boston, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="ISSN">1525-4135</idno><idno type="eISSN">1944-7884</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title><p id="P1">The possible impact of co-infection with Kaposi’s sarcoma associated herpes virus on the response to antiretroviral therapy (ART) is unknown. Prospective studies are rare, particularly in Africa.</p></sec><sec id="S2"><title>Methods</title><p id="P2">We enrolled a prospective cohort of HIV-infected adults initiating ART in Johannesburg, South Africa. Subjects were defined as seropositive to KSHV if reactive to either KSHV lytic K8.1 or latent Orf73 antigen or both. Subjects were followed from ART initiation until 18-months on treatment. HIV viral load and CD4 counts were tested 6 monthly. Linear generalized estimating and log-binomial regression models were used to estimate the effect of KSHV infection on immunologic recovery and response as well as HIV viral load suppression within 18-months after ART initiation.</p></sec><sec id="S3"><title>Results</title><p id="P3">385 subjects initiating ART from November 2008-March 2009 were eligible including 184 (48%) KSHV+. The KSHV+ group was similar to the KSHV− in terms of age, gender, initiating CD4 count, body mass index, tuberculosis and haemoglobin levels. The KSHV+ group gained a similar number of cells at 6- (difference of 10 cells/mm<sup>3</sup>, 95% CI: −11–31), 12- (3 cells/mm<sup>3</sup>, 95% CI: −19–25) and 18-months (24 cells/mm<sup>3</sup>, 95% CI: −13–61) compared to the KSHV− group. Adjusted relative risk of failure to suppress viral load to <400 copies/mL (1.03; 95% CI: 0.90–1.17) were similar for KSHV+ and KSHV− by 6-months on treatment.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">In a population with a high KSHV prevalence, HIV-positive adults co-infected with KSHV achieved similar immunologic and virologic responses to ART early after treatment initiation compared to those KSHV−.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">100892005</journal-id><journal-id journal-id-type="pubmed-jr-id">21821</journal-id><journal-id journal-id-type="nlm-ta">J Acquir Immune Defic Syndr</journal-id><journal-id journal-id-type="iso-abbrev">J. Acquir. Immune Defic. Syndr.</journal-id><journal-title-group><journal-title>Journal of acquired immune deficiency syndromes (1999)</journal-title></journal-title-group><issn pub-type="ppub">1525-4135</issn><issn pub-type="epub">1944-7884</issn></journal-meta><article-meta><article-id pub-id-type="pmid">23614996</article-id><article-id pub-id-type="pmc">3712196</article-id><article-id pub-id-type="doi">10.1097/QAI.0b013e3182969cc1</article-id><article-id pub-id-type="manuscript">NIHMS481532</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Kaposi sarcoma-associated herpesvirus and response to antiretroviral therapy: A prospective study of HIV-infected adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maskew</surname><given-names>Mhairi</given-names></name><degrees>MBBCh, MSc Med</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>MacPhail</surname><given-names>A Patrick</given-names></name><degrees>PhD, FRCP</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Whitby</surname><given-names>Denise</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Egger</surname><given-names>Matthias</given-names></name><degrees>MD, MSc, MFPHM, DTM & H</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Matthew P.</given-names></name><degrees>DSc, MPH</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib></contrib-group><aff id="A1"><label>1</label>Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</aff><aff id="A2"><label>2</label>Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg</aff><aff id="A3"><label>3</label>Viral Oncology Section, AIDS and Cancer Virus Program, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick MD, USA</aff><aff id="A4"><label>4</label>Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland</aff><aff id="A5"><label>5</label>Center for Global Health and Development, Boston, USA</aff><aff id="A6"><label>6</label>Department of Epidemiology, Boston University School of Public Health, Boston, USA</aff><author-notes><corresp id="cor1"><bold>Corresponding Author and Address for Reprints:</bold> Dr Mhairi Maskew, Health Economics and Epidemiology Research Office, Themba Lethu Clinic, Helen Joseph Hospital, Perth Road, Westdene, Johannesburg, South Africa, 2192, Phone: +27-11-276-8850, Fax: +27 86 516 0628, <email>mmaskew@heroza.org</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>15</day><month>6</month><year>2013</year></pub-date><pub-date pub-type="ppub"><day>1</day><month>8</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>8</month><year>2014</year></pub-date><volume>63</volume><issue>4</issue><fpage>442</fpage><lpage>448</lpage><abstract><sec id="S1"><title>Background</title><p id="P1">The possible impact of co-infection with Kaposi’s sarcoma associated herpes virus on the response to antiretroviral therapy (ART) is unknown. Prospective studies are rare, particularly in Africa.</p></sec><sec id="S2"><title>Methods</title><p id="P2">We enrolled a prospective cohort of HIV-infected adults initiating ART in Johannesburg, South Africa. Subjects were defined as seropositive to KSHV if reactive to either KSHV lytic K8.1 or latent Orf73 antigen or both. Subjects were followed from ART initiation until 18-months on treatment. HIV viral load and CD4 counts were tested 6 monthly. Linear generalized estimating and log-binomial regression models were used to estimate the effect of KSHV infection on immunologic recovery and response as well as HIV viral load suppression within 18-months after ART initiation.</p></sec><sec id="S3"><title>Results</title><p id="P3">385 subjects initiating ART from November 2008-March 2009 were eligible including 184 (48%) KSHV+. The KSHV+ group was similar to the KSHV− in terms of age, gender, initiating CD4 count, body mass index, tuberculosis and haemoglobin levels. The KSHV+ group gained a similar number of cells at 6- (difference of 10 cells/mm<sup>3</sup>, 95% CI: −11–31), 12- (3 cells/mm<sup>3</sup>, 95% CI: −19–25) and 18-months (24 cells/mm<sup>3</sup>, 95% CI: −13–61) compared to the KSHV− group. Adjusted relative risk of failure to suppress viral load to <400 copies/mL (1.03; 95% CI: 0.90–1.17) were similar for KSHV+ and KSHV− by 6-months on treatment.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">In a population with a high KSHV prevalence, HIV-positive adults co-infected with KSHV achieved similar immunologic and virologic responses to ART early after treatment initiation compared to those KSHV−.</p></sec></abstract><kwd-group><kwd>Kaposi sarcoma herpesvirus</kwd><kwd>antiretroviral therapy</kwd><kwd>resource-poor setting</kwd><kwd>virologic suppression</kwd></kwd-group><funding-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>U01 AI069924 || AI</award-id></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001913 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001913 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3712196
|texte= Kaposi sarcoma-associated herpesvirus and response to antiretroviral therapy: A prospective study of HIV-infected adults
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23614996" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |